University of Nebraska Medical Center

New Study Warns About Impending Financial Cliff for Nebraska’s Early Childhood System

Retrieved on: 
Wednesday, August 9, 2023
Workforce, Learning, State, University, Education, Technical Report Archive & Image Library, History of early childhood care and education, Policy, COVID-19, Research, Child care, Investment, Child, University of Nebraska Medical Center, Pharmaceutical industry, Toy

This comes as a new analysis from the Buffett Institute suggests that Nebraska is still not fully funding early childhood care and education.

Key Points: 
  • This comes as a new analysis from the Buffett Institute suggests that Nebraska is still not fully funding early childhood care and education.
  • The new brief builds on the work of the Nebraska Early Childhood Workforce Commission , which called for fully funding the state’s early childhood system by 2030.
  • “The Nebraska Early Childhood Funding Map helps users see the current complexity involved in financing Nebraska’s early childhood system while also exploring individual pathways within it,” said Huddleston-Casas.
  • The Buffett Early Childhood Institute at the University of Nebraska promotes the development and learning of children from birth through age 8.

PreludeDx Appoints Dr. Leona Hamrick as Senior Director, Medical Affairs

Retrieved on: 
Thursday, August 3, 2023
Bachelor of Science in Nursing, Lumicel Animation Studios, Medical Affairs Bureau, University, Quality of life, Nebraska Medicine, University of Nebraska Medical Center, Nova Southeastern University, Patient, Physician, Medicine, Mountain State University, DCIS, Breast cancer, Nursing, Science

LAGUNA HILLS, Calif., Aug. 3, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced the appointment of Dr. Leona Hamrick DHSc, PA-C, MSL-BC to the newly created position of Senior Director, Medical Affairs. This role is a strategic addition to the leadership team as PreludeDx accelerates adoption, educations and advocacy of its ductal carcinoma in situ (DCIS) risk assessment test, DCISionRT.

Key Points: 
  • LAGUNA HILLS, Calif., Aug. 3, 2023 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today announced the appointment of Dr. Leona Hamrick DHSc, PA-C, MSL-BC to the newly created position of Senior Director, Medical Affairs.
  • Dr. Hamrick brings nearly three decades of experience in the medical field, first as a healthcare provider and adjunct professor and then as a patient advocate and medical affairs liaison.
  • She joins PreludeDx from Biodesix where she served as the VP, Clinical Development & Medical Affairs and was responsible for worldwide medical affairs strategy and execution.
  • "I'm inspired by PreludeDx's commitment to advancing precision medicine for early-stage breast cancer patients and their physicians," said Hamrick.

Glytec Brings Health System Leaders, Clinicians and Industry Experts Together for Third-Annual Time to Target Conference

Retrieved on: 
Wednesday, July 26, 2023
Software, Practice Management, Health, FDA, Diabetes, Data Management, Hospitals, Technology, UC Davis Medical Center, Insulin resistance, CMS, University, Metabolism, Centers for Medicare & Medicaid Services, Culture, Nebraska Medicine, University of Nebraska Medical Center, Research, Hyperglycemia, Medicare, Blood, Hospital, Hypoglycemia, Patient, Division, Disease, Endocrinology, Mortality, Pharmaceutical industry, Medical device, Target

There is no cost to attend the conference, which will be held virtually on October 25-26, 2023.

Key Points: 
  • There is no cost to attend the conference, which will be held virtually on October 25-26, 2023.
  • Glycemic management challenges extend beyond people living with diabetes, cutting across disease states and reasons for admission and impacting every hospital department.
  • We’re proud to have Glytec customers speak at this event each year because their guidance and successes underpin the evolution of the industry.
  • For more information about the event, including the agenda, a list of confirmed speakers and registration details, visit https://www.glytectimetotarget.com/ .

LARGEST STUDY ON RACIAL DIFFERENCES IN MEN WITH MELANOMA SHOWS MEN WITH SKIN OF COLOR HAVE LOWEST SURVIVAL RATES

Retrieved on: 
Tuesday, July 11, 2023
Survival rate, Melanoma, Extremities, University, Social conditions in Honduras, Bleeding, University of Nebraska Medical Center, DIAMETER, Survival, Skin cancer, Truth: Red, White & Black, Nail, Journal of the American Academy of Dermatology, Woman, American Academy, Nebraska Medicine, Research, Factorization of polynomials, FAAD, Hormone, Journal, MD, Patient, Immune system, COLOR, Diagnosis, Health, Death, Rest, Skin, Medical imaging, Silviculture, Dermatology, Black, White

ROSEMONT, Ill., July 11, 2023 /PRNewswire/ -- Melanoma, the most serious form of skin cancer, is highly treatable when detected early, but when the disease advances, it can lead to death. A new article published in the Journal of the American Academy of Dermatology reveals that men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma.

Key Points: 
  • A new article published in the Journal of the American Academy of Dermatology reveals that men with melanoma – and particularly men with skin of color – are more likely to die than women with melanoma.
  • The analysis involved more than 200,000 participants and is the largest study to date on racial differences in men with melanoma.
  • It compared melanoma diagnosis data from the National Cancer Database from 2004 until 2018 in White, Black, Asian, American Indian/Alaskan Native, and Hispanic men.
  • Overall survival rates in men with melanoma were highest for White men (75 percent), followed by American Indian/Alaskan Native (69 percent), Asian (68 percent), Hispanic (66 percent), and Black men (52 percent).

National Cancer Center Announces Recipients of 2023-24 Research Fellowship Awards

Retrieved on: 
Thursday, June 29, 2023
Research, Philanthropy, Pharmaceutical, Oncology, Hospitals, University, Genetics, Education, Foundation, Clinical Trials, Science, Biotechnology, Health, UPMC Hillman Cancer Center, DNA, Cleveland Clinic, Duke University Hospital, University of Pittsburgh, NCC, Brain, Therapy, Swansea University Medical School, Prostate cancer, Follicular lymphoma, Johns Hopkins School of Medicine, Cancer, Nebraska Medicine, Coronavirus Scientific Advisory Board, Woman, DNA repair, University of Nebraska Medical Center, Breast, University of California, Colon, Harvard Medical School, National Cancer Center, City, Prostate Cancer Foundation, Melanoma, Rockefeller University, Baylor College of Medicine, Diagnosis, New York University Grossman School of Medicine, Tobacco Products Scientific Advisory Committee, Dana–Farber Cancer Institute, Pharmaceutical industry, Interior design, Doctor of Philosophy, New York University

The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research.

Key Points: 
  • The National Cancer Center is pleased to announce the recipients of its 2023-24 research grant awards, which support research fellows pursuing promising and innovative cancer research.
  • National Cancer Center is delighted to report that total funding for the 2023-24 year grew by 9.4% to an annual record of $768,000.
  • “For 70 years, National Cancer Center has sought to identify and fund promising projects by the best up-and-coming cancer research fellows,” said Regina English, Executive Director of the National Cancer Center.
  • The NCC runs six cancer research programs: Aggressive Cancer Project; Fighting Childhood Leukemia; the Breast Cancer Project; Children’s Cancer Project; Prostate Cancer Project and the NCC Project, which focuses on research showing particular promise for brain tumors, melanoma, DNA repair, anti-cancer therapies, gene mutations and targeted therapeutics.

Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors

Retrieved on: 
Friday, June 23, 2023
Orexigen Therapeutics, Amgen, Duke University Hospital, University, Senior, University of Nebraska Medical Center, Internal medicine, Arena Pharmaceuticals, Nephrology, Nebraska Medicine, MicroRNA, CMO, Science, Regulus Therapeutics, SAN, ADPKD, Therapy, Transgene (company), Management, Research, Regulus

"We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.

Key Points: 
  • "We are delighted to have Dr. Klassen join our board during this exciting time for Regulus, as we advance the clinical development of RGLS8429 for the treatment of ADPKD," said Stelios Papadopoulos, Ph.D., Chairman of the Board of Directors of Regulus.
  • "His expertise in nephrology, along with his previous leadership and board experience in the industry, will make him an invaluable member, and we look forward to his contributions to Regulus and our science."
  • Preston Klassen, M.D., recently joined Regulus Therapeutics as President and Head of Research and Development.
  • Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology.

Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)

Retrieved on: 
Tuesday, June 20, 2023
Education, Health, FDA, Other Health, Clinical Trials, University, Biotechnology, Neuroprotection, Partnership, Credibility, University of Nebraska Medical Center, COYA, Uneme language, Coya, Interleukin 2, Mouse, AD, Therapy, ALS, Pharmaceutical industry, PD

Under the terms of the agreement with UNeMed, Coya has been granted the exclusive patent rights and know-how for use of ld IL-2 and ld IL-2 combinations for PD.

Key Points: 
  • Under the terms of the agreement with UNeMed, Coya has been granted the exclusive patent rights and know-how for use of ld IL-2 and ld IL-2 combinations for PD.
  • UNeMed will receive payments upon achievement of certain milestones and will also be eligible to receive tiered low-single digit royalty on net sales.
  • “We believe that Treg dysfunction is the common thread that binds together many neurodegenerative diseases.
  • Furthermore, the treatment had a potent neuroprotective effect on nigral dopaminergic neurons in affected mice.

AIM ImmunoTech Outlines Recent Significant Progress Across Clinical Development Pipeline and Provides Update on Positive Pre-Clinical and IP Developments

Retrieved on: 
Monday, June 12, 2023
CIPC, TNBC, Pancreatic cancer, Roswell Park Comprehensive Cancer Center, AIM, University, Therapy, University of Nebraska Medical Center, TLR3, Methods used to study memory, Intron, LAPC, RNA, Number, Survival, Clinical trial, SITC, Celecoxib, Nebraska Medicine, Viral, Research, Neoplasm, Biomarker, FOLFIRINOX, ClinicalTrials.gov, Doctor of Philosophy, PCR, South African patent system, Pancreas, Erasmus MC, Cancer, Publication, Professor, MD, DSM-IV codes, Blood, Annual general meeting, Peripheral, Roswell, B cell, NYSE, Safety, Vaccine, Pharmaceutical industry, Nursing, Ebola, Rintatolimod, Patient

Ampligen continues to demonstrate significant potential across multiple types of cancers, immune disorders and viral diseases.

Key Points: 
  • Ampligen continues to demonstrate significant potential across multiple types of cancers, immune disorders and viral diseases.
  • AMP-270 is expected to enroll approximately 90 subjects in up to 30 centers across the United States and Europe.
  • The Company is recruiting patients for its AMP-270 Phase 2 study of Ampligen as a therapy for LAPC.
  • The lead site at the University of Nebraska Medical Center is now open and actively working to enroll patients.

Regulus Therapeutics Strengthens Research & Development Leadership

Retrieved on: 
Monday, June 12, 2023
Orexigen Therapeutics, Amgen, Employment, University, Duke University Hospital, Biochemistry, University of Nebraska Medical Center, Doctor of Philosophy, Internal medicine, Arena Pharmaceuticals, Senior, Nephrology, CMC, Nebraska Medicine, MicroRNA, CMO, Regulus Therapeutics, Chemistry, Cardinal Health, Patient, SAN, Regulus, Preston, Kidney, Amylin Pharmaceuticals, Therapy, Kidney disease, Pharmaceutical industry, Management, Indiana University, Allergan, ADPKD, Research

SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development. Dr. Klassen brings over 20 years of experience in leadership roles in both large and small biopharmaceutical companies. In addition, the Company announced the appointment of Curtis A. Monnig, Ph.D., to Vice President of CMC. 

Key Points: 
  • SAN DIEGO, June 12, 2023 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today announced the appointment of Preston S. Klassen M.D., M.H.S., to President and Head of Research and Development.
  • "We are thrilled to welcome Dr. Klassen to the Regulus team," said Jay Hagan, Chief Executive Officer of Regulus Therapeutics.
  • Dr. Preston Klassen is an established nephrologist who brings years of experience in leadership, medical affairs, and research and development across multiple therapeutic areas.
  • Previously, while at Amgen, he held multiple leadership roles, including Executive Medical Director and Therapeutics Area Head for Nephrology.

Virtual Reality Brings Clinical Education into a New Dimension

Retrieved on: 
Friday, May 26, 2023
Village, Medical simulation, University, University of Nebraska Medical Center, Health care, Nebraska Medicine, Decision Sciences Journal of Innovative Education, Medicine, Augmented World Expo, VR, CO, University of Pennsylvania School of Nursing, Virtual reality, Knowledge, Belk, Augment, Air Methods, Nursing

He will share his insights and experiences on using cutting-edge technology to revolutionize air medical training and critical care education.

Key Points: 
  • He will share his insights and experiences on using cutting-edge technology to revolutionize air medical training and critical care education.
  • “At Air Methods , we are constantly seeking new ways to improve the skills and knowledge of our medical personnel, and the use of virtual reality has been a game-changer,” said Belk.
  • These healthcare simulation and training leaders will discuss their extensive experiences integrating virtual reality into their healthcare simulation enterprises.
  • They will also share some of the lessons they’ve learned about the benefits and challenges of VR in medical training, as well as best practices for both users and educators in medicine.